TRAIL (TNF-Related Apoptosis-Inducing Ligand) is a recent therapeutic opportunity to treat aggressive melanoma that presents high selectivity to cancer cells but also applicability limitations due to development of resistance. The gene discussed is TNFSF10; the disease is cancer.